HealthCore, Inc.; Wilmington, DE USA.
Hum Vaccin Immunother. 2013 Feb;9(2):389-97. doi: 10.4161/hv.22877. Epub 2013 Jan 4.
This retrospective study determined the level of compliance to rotavirus vaccination guidelines within a large, commercially insured US population, as well as compliance with PI, ACIP and HEDIS measures for rotavirus vaccination.
Medical and pharmacy claims were obtained from the HealthCore Integrated Research Database. Enrolled children were stratified into PI, ACIP and HEDIS cohorts. The PI cohort was subdivided into RV5 and RV1 cohorts due to the differences in dosing schedules and patients with mixed dosing were excluded from the these two cohorts. Patients identified in the HEDIS cohort were linked to the administering physicians.
Of 162,614 patients in PI cohort, 27% did not receive rotavirus vaccinations, 24% (RV5) and 15% (RV1) had incomplete doses (p < 0.0001; RV1 vs. RV5). A total of 76% of patients completed RV5 series but not on schedule, 54% completed on schedule. A total of 85% of patients completed the RV1 series at any time, 69% completed on schedule. Among health plans, 53% of patients completed the series, 22% (RV5) and 15% (RV1) had incomplete doses (p < 0.0001). Of 2,086 physicians who treated ≥ 10 patients within the plan (regardless of vaccination status), 78% had > 50% of patients complete, 22% had > 90% of patients completed.
Despite both two effective rotavirus vaccines and national immunization recommendations, rotavirus vaccination remains underutilized for infants.
本回顾性研究旨在确定在美国大型商业保险人群中,轮状病毒疫苗接种指南的遵从程度,以及轮状病毒疫苗接种的 PI、ACIP 和 HEDIS 措施的遵从程度。
从 HealthCore 综合研究数据库获取医疗和药房索赔。将入组儿童分为 PI、ACIP 和 HEDIS 队列。由于给药方案的差异,PI 队列分为 RV5 和 RV1 队列,并且混合剂量的患者被排除在这两个队列之外。HEDIS 队列中的患者与负责接种的医生相关联。
在 PI 队列的 162614 名患者中,27%未接受轮状病毒疫苗接种,24%(RV5)和 15%(RV1)未完成全剂量接种(p<0.0001;RV1 与 RV5 相比)。76%的患者完成了 RV5 系列接种,但未按计划完成,54%的患者按计划完成。85%的患者在任何时候都完成了 RV1 系列接种,69%的患者按计划完成。在不同的健康计划中,53%的患者完成了系列接种,22%(RV5)和 15%(RV1)未完成全剂量接种(p<0.0001)。在治疗该计划内≥10 名患者的 2086 名医生中,78%的医生有超过 50%的患者完成了接种,22%的医生有超过 90%的患者完成了接种。
尽管有两种有效的轮状病毒疫苗和国家免疫建议,但轮状病毒疫苗接种在婴儿中的使用率仍然较低。